Deutsche Bank AG Sells 102,947 Shares of AtriCure, Inc. (NASDAQ:ATRC)

Deutsche Bank AG lessened its stake in AtriCure, Inc. (NASDAQ:ATRC - Free Report) by 69.4% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 45,459 shares of the medical device company's stock after selling 102,947 shares during the quarter. Deutsche Bank AG owned 0.09% of AtriCure worth $1,389,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently made changes to their positions in ATRC. Hood River Capital Management LLC lifted its position in AtriCure by 3.3% in the 4th quarter. Hood River Capital Management LLC now owns 2,923,731 shares of the medical device company's stock valued at $89,349,000 after acquiring an additional 93,131 shares in the last quarter. First Light Asset Management LLC raised its stake in shares of AtriCure by 5.6% in the 4th quarter. First Light Asset Management LLC now owns 1,969,221 shares of the medical device company's stock valued at $60,179,000 after purchasing an additional 103,685 shares during the period. Kennedy Capital Management LLC lifted its holdings in shares of AtriCure by 29.8% in the fourth quarter. Kennedy Capital Management LLC now owns 752,580 shares of the medical device company's stock valued at $22,999,000 after purchasing an additional 172,648 shares in the last quarter. Dimensional Fund Advisors LP boosted its position in shares of AtriCure by 24.1% during the fourth quarter. Dimensional Fund Advisors LP now owns 700,212 shares of the medical device company's stock worth $21,398,000 after buying an additional 136,015 shares during the period. Finally, Marshall Wace LLP grew its holdings in shares of AtriCure by 37.1% during the fourth quarter. Marshall Wace LLP now owns 619,166 shares of the medical device company's stock worth $18,922,000 after buying an additional 167,476 shares in the last quarter. Institutional investors and hedge funds own 99.11% of the company's stock.

Wall Street Analysts Forecast Growth

Several research firms have commented on ATRC. Piper Sandler boosted their target price on AtriCure from $40.00 to $50.00 and gave the company an "overweight" rating in a research note on Thursday, February 13th. JMP Securities reissued a "market outperform" rating and issued a $60.00 price objective on shares of AtriCure in a research report on Wednesday, April 30th. Needham & Company LLC decreased their target price on shares of AtriCure from $51.00 to $44.00 and set a "buy" rating for the company in a research report on Wednesday, April 30th. Oppenheimer boosted their price target on shares of AtriCure from $36.00 to $45.00 and gave the stock an "outperform" rating in a research report on Thursday, February 13th. Finally, BTIG Research restated a "buy" rating on shares of AtriCure in a research note on Thursday, March 27th. Ten analysts have rated the stock with a buy rating, Based on data from MarketBeat, AtriCure has an average rating of "Buy" and a consensus target price of $50.67.

Insider Activity

In related news, Director Karen Prange sold 6,100 shares of the stock in a transaction on Wednesday, March 5th. The stock was sold at an average price of $38.12, for a total value of $232,532.00. Following the sale, the director now owns 17,828 shares in the company, valued at approximately $679,603.36. This represents a 25.49% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 3.50% of the company's stock.

AtriCure Stock Performance

ATRC stock traded up $0.54 during trading hours on Thursday, reaching $34.08. The stock had a trading volume of 531,987 shares, compared to its average volume of 649,696. The stock has a 50-day simple moving average of $32.32 and a 200 day simple moving average of $34.73. AtriCure, Inc. has a fifty-two week low of $18.94 and a fifty-two week high of $43.11. The stock has a market capitalization of $1.69 billion, a PE ratio of -35.87 and a beta of 1.57. The company has a debt-to-equity ratio of 0.13, a current ratio of 3.65 and a quick ratio of 2.62.

AtriCure (NASDAQ:ATRC - Get Free Report) last issued its earnings results on Tuesday, April 29th. The medical device company reported ($0.14) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.25) by $0.11. The business had revenue of $123.62 million during the quarter, compared to the consensus estimate of $122.92 million. AtriCure had a negative net margin of 9.61% and a negative return on equity of 6.80%. AtriCure's revenue was up 13.5% on a year-over-year basis. During the same period last year, the business posted ($0.28) EPS. Analysts predict that AtriCure, Inc. will post -0.6 EPS for the current fiscal year.

AtriCure Company Profile

AtriCure, Inc develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, Europe, the Asia-Pacific, and internationally. The company offers Isolator Synergy Clamps, single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation, and ablate cardiac tissue with the same device; and the Coolrail device, which enables users to make longer linear lines of ablation.